Development
Gilead Sciences, Inc.
GILD
$112.46
-$2.05-1.79%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 27.12B | 27.39B | 27.38B | 27.04B | 27.28B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.12B | 27.39B | 27.38B | 27.04B | 27.28B |
| Cost of Revenue | 5.97B | 5.80B | 5.63B | 5.63B | 5.66B |
| Gross Profit | 21.14B | 21.59B | 21.75B | 21.41B | 21.62B |
| SG&A Expenses | 6.09B | 6.50B | 6.40B | 5.91B | 5.67B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.77B | 18.18B | 17.57B | 16.78B | 16.29B |
| Operating Income | 9.34B | 9.21B | 9.81B | 10.26B | 11.00B |
| Income Before Tax | 6.86B | 7.24B | 7.35B | 7.27B | 5.81B |
| Income Tax Expenses | 1.25B | 1.41B | 1.91B | 1.73B | 1.25B |
| Earnings from Continuing Operations | 5.61K | 5.83K | 5.44K | 5.54K | 4.57K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 52.00M | 47.00M | 42.00M | 45.00M | 26.00M |
| Net Income | 5.66B | 5.88B | 5.48B | 5.58B | 4.59B |
| EBIT | 9.34B | 9.21B | 9.81B | 10.26B | 11.00B |
| EBITDA | 12.04B | 11.75B | 12.19B | 12.48B | 13.10B |
| EPS Basic | 4.54 | 4.70 | 4.38 | 4.46 | 3.66 |
| Normalized Basic EPS | 4.43 | 4.34 | 4.60 | 4.78 | 5.07 |
| EPS Diluted | 4.49 | 4.66 | 4.35 | 4.43 | 3.64 |
| Normalized Diluted EPS | 4.40 | 4.31 | 4.56 | 4.75 | 5.04 |
| Average Basic Shares Outstanding | 4.99B | 5.00B | 5.00B | 5.01B | 5.02B |
| Average Diluted Shares Outstanding | 5.03B | 5.04B | 5.04B | 5.05B | 5.05B |
| Dividend Per Share | 3.00 | 2.98 | 2.96 | 2.94 | 2.92 |
| Payout Ratio | 67.25% | 64.36% | 68.51% | 66.86% | 80.77% |